[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601093":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":7,"responsibleParty":14,"collaborators":7,"id":17,"slug":18,"hasResults":19,"nctId":20,"briefTitle":21,"officialTitle":22,"acronym":7,"eligibilityCriteria":23,"healthyVolunteers":19,"sex":24,"minAge":25,"maxAge":26,"enrollmentInfo":27,"targetDuration":7,"studyType":30,"phases":7,"briefSummary":31,"conditions":32,"keywords":7,"overallStatus":34,"whyStopped":7,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":7},{"fullName":5,"class":6},"Nanjing First Hospital, Nanjing Medical University","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Feng Wang","CONTACT","+8602552271491","fengwangcn@hotmail.com",{"type":15,"investigatorFullName":10,"investigatorTitle":16,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Chief physician","100601093","radiolabeled-tspo-targeted-molecular-probe-in-glioma-100601093",false,"NCT07106008","Radiolabeled TSPO Targeted Molecular Probe in Glioma","Clinical Application of a Novel Radiolabeled Translocator Protein (TSPO) Targeted Small Molecular Probe in Neuroinflammation Imaging of Glioma","Inclusion Criteria:\n\n* Voluntary subjects, patients, or their legal representatives must sign the informed consent form.\n* There are no restrictions on the gender of volunteers; age must be between 18 and 75 years, inclusive.\n* Other imaging examination methods (e.g., CT, MRI) show the presence of intracranial lesions.\n* Patients with brain glioma who are scheduled for surgery or biopsy that will provide final pathological results.\n* Patients must have a kidney GFR \\> 50 mL\u002Fmin, ERPF \\> 280 mL\u002Fmin, platelet count (PLT) \\> 75,000\u002FμL, white blood cell count (WBC) \\> 3,000\u002FμL, and alanine aminotransferase (ALT) and asparta.\n\nExclusion Criteria:\n\n* Individuals with a history of allergy to drugs with similar chemical or biological components to TSPO, a history of atopy, or currently suffering from allergic diseases.\n* Individuals currently participating in other drug clinical studies, or who have previously participated in any drug (excluding vitamins and minerals) clinical studies.\n* Individuals with other difficult-to-control clinical conditions, such as HIV infection, hepatitis C virus infection, active hepatitis B, other severe chronic infections, or serious mental, neurological, cardiovascular, respiratory, or other systemic diseases.\n* Red blood cell count (RBC) \\\u003C 4×10\\^12\u002FL, white blood cell count (WBC) \\\u003C 3×10\\^9\u002FL, hemoglobin \\\u003C 110 g\u002FL, platelet count (PLT) \\\u003C 75×10\\^9\u002FL.\n* Significant liver and kidney function abnormalities, glomerular filtration rate (GFR) \\\u003C 50 ml\u002Fmin.\n* Tumor burden involving more than 50% of the affected organ, or significant spinal cord compression.\n* Expected survival time less than six months, or having received chemotherapy within the past six months.\n* Individuals with severe acute comorbidities or severe refractory mental disorders.\n* Pregnant or breastfeeding women (pregnancy defined as a positive urine pregnancy test).\n* Individuals whose physical condition is unsuitable for radioactive examination.\n* Other circumstances deemed unsuitable for participation in the trial by the investigator.","ALL","18 Years","75 Years",{"count":28,"type":29},8,"ESTIMATED","OBSERVATIONAL","Evaluate the clinical application value of the novel radiolabeled TSPO-targeted molecular probe Gallium \\[68Ga\\]-DOTA-HK-011 in inflammation imaging of glioma.",[33],"Glioma (Any Grade) in the Brain","NOT_YET_RECRUITING","2025-07-30",{"date":37,"type":38},"2025-08-06","ACTUAL",{"date":40,"type":29},"2025-09-01",{"date":42,"type":29},"2026-08-31",{"name":5,"class":6}]